Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.panaceabiotec.com | |
Market Cap | 746.03 Cr. | |
Enterprise Value(EV) | 492.69 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 187.40 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 0.65 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.22 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 131.94 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 0.92 | Calculated using Price: 121.55 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 6.13 Cr. | 61,250,746 Shares |
FaceValue | 1 | |
Company Profile | ||
The company has product portfolio that's caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal. Business Areas of the Company :- (1) Research and Development (R&D) – Under this the company primarily focuses on New Chemical Entities (NCE), New Biological Entities (NBE) and Novel Drug Delivery System (NDDS). (2) Vaccines- Under this the company has product portfolio of oral polio vaccines and Hepatitis-B vaccines. (3) Formulations- It has created flagship brands like Willgo for pain management, Glizid & Glizid-M for diabetes; Panimun Bioral and Mycept for kidney transplant. |
1 Day |
|
-3.22% |
1 Week |
|
-4.67% |
1 Month |
|
-14.13% |
3 Month |
|
-14.01% |
6 Month |
|
-13.61% |
1 Year |
|
-51.51% |
2 Year |
|
-44.00% |
5 Year |
|
-56.08% |
10 Year |
|
-6.03% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | -76.49 | -253.03 | -34.38 | -22.94 | 11.39 | -75.26 | 347.66 | |||
Return on Capital Employed (%) | 3.37 | 0.45 | 9.93 | 2.76 | 2.63 | 13.44 | -0.38 | 5.36 | 221.15 | |
Return on Assets (%) | -5.47 | -4.87 | -1.01 | -2.97 | -4.53 | 2.55 | -13.36 | -10.69 | 73.58 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 513 | 471 | 449 | 356 | 309 | 350 | 199 | -229 | 849 | 808 | |
Non Curr. Liab. | 767 | 918 | 1,100 | 719 | 591 | 70 | 741 | 960 | 104 | 118 | |
Curr. Liab. | 827 | 706 | 475 | 689 | 696 | 938 | 622 | 449 | 803 | 410 | |
Minority Int. | 5 | 3 | 1 | 11 | -3 | -3 | -3 | -3 | -3 | -3 | |
Equity & Liab. | 2,112 | 2,099 | 2,025 | 1,774 | 1,592 | 1,356 | 1,559 | 1,177 | 1,752 | 1,333 | |
Non Curr. Assets | 1,739 | 1,573 | 1,475 | 1,071 | 1,028 | 848 | 875 | 666 | 712 | 664 | |
Curr. Assets | 373 | 526 | 549 | 703 | 565 | 508 | 683 | 511 | 1,041 | 670 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 2,112 | 2,099 | 2,025 | 1,774 | 1,592 | 1,356 | 1,559 | 1,177 | 1,752 | 1,333 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 510 | 687 | 653 | 544 | 593 | 457 | 544 | 625 | 661 | 512 | |
Other Income | 15 | 28 | 20 | 47 | 8 | 5 | 30 | 10 | 11 | 28 | |
Total Income | 525 | 716 | 673 | 591 | 601 | 462 | 574 | 635 | 672 | 541 | |
Total Expenditure | -592 | -643 | -541 | -497 | -508 | -590 | -519 | -548 | -675 | -614 | |
PBIDT | -67 | 72 | 132 | 94 | 93 | -128 | 56 | 87 | -3 | -74 | |
Interest | -150 | -105 | -127 | -101 | -101 | -105 | -174 | -185 | -181 | -85 | |
Depreciation | -71 | -67 | -73 | -68 | -59 | -55 | -44 | -46 | -44 | -42 | |
Taxation | -2 | -3 | -2 | 11 | -10 | -9 | -17 | -2 | -371 | -383 | |
Exceptional Items | 177 | 50 | 8 | 334 | -15 | 1,676 | 1,732 | ||||
PAT | -113 | -102 | -21 | -56 | -76 | 38 | -195 | -146 | 1,078 | 1,148 | |
Minority Interest | 1 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | ||
Share Associate | -1 | -6 | 0 | 0 | 0 | 0 | 0 | ||||
Other Related Items | |||||||||||
Consolidated Net Profit | -112 | -107 | -18 | -54 | -74 | 38 | -194 | -148 | 1,078 | 1,148 | |
Adjusted EPS | -18 | -17 | -3 | -9 | -12 | 6 | -32 | -24 | 176 | 187 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | -24 | 54 | 37 | 91 | 131 | 118 | 105 | -30 | 107 | -108 | |
Cash Fr. Inv. | -61 | -38 | -37 | 16 | -26 | 55 | -5 | -35 | -48 | 1,283 | |
Cash Fr. Finan. | 105 | -30 | -1 | -117 | -107 | -164 | -101 | 91 | -47 | -1,176 | |
Net Change | 20 | -14 | -1 | -10 | -2 | 9 | -2 | 26 | 12 | -2 | |
Cash & Cash Eqvt | 35 | 21 | 20 | 10 | 7 | 16 | 14 | 40 | 52 | 50 |
Wed, 01 Feb 2023
Board Meeting Intimation for Approving The Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter And NineMonths Ended December 31 2022 PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended December 31 2022.With reference to our earlier announcement dated December 29 2022 intimating the Closure of Trading Window pursuant to the Companys Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time the trading window of the Company shall remain closed for all Designated Persons of the Company till February 16 2023and the same will re-open from February 17 2023. |
Tue, 17 Jan 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release Panacea Biotec Ltd. has on humanitarian grounds donated 125 000 single dose vials (SDVs) of its WHO Prequalified Pentavalent vaccine Easyfive- IT to the Ministry of Health ofRepublic of Cuba for use in Cuba National Health System specifically in the expanded immunization program due to current ongoing shortage of the wP based Pentavalent Vaccine in Cuba.A copy of the Press Release being issued to the media etc. in this regard is enclosed. |
Fri, 06 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 We are enclosing herewith a certificate dated January 04 2023 issued by Skyline Financial Services Private Limited Registrar and Transfer Agent of the Company confirming compliance under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended December 31 2022. |
Fri, 03 Feb 2023 |
|
|
|
|
|